Rani Therapeutics Holdings Inc Quick Ratio (RANI) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rani Therapeutics Holdings Inc   (NASDAQ: RANI)

Rani Therapeutics Holdings Inc 's Quick Ratio

RANI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Rani Therapeutics Holdings Inc 's Cash & cash equivalent grew by 23.01 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Rani Therapeutics Holdings Inc 's Quick Ratio to 5.02, Quick Ratio remained below Rani Therapeutics Holdings Inc average.

Within Major Pharmaceutical Preparations industry 199 other companies have achieved higher Quick Ratio than Rani Therapeutics Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 876, from total ranking in the first quarter 2026 at 978.

Explain Quick Ratio?
How much Cash & cash equivalents RANI´s has?
What are RANI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RANI Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -48.42 % -38.43 % -31.8 % -5.28 % 24.38 %
Y / Y Cash & cash equivalent Change 422.62 % 173.78 % 79.85 % -86.37 % -66.94 %
Quick Ratio MRQ 5.02 3.5 3.66 0.22 0.5
RANI's Total Ranking # 876 # 978 # 1608 # 1213 #
Seq. Current Liabilities Change -14.18 % -8.63 % -29.14 % -7.17 % 2.45 %
Seq. Cash & cash equivalent Change 23.01 % -12.69 % 1099.54 % -59.44 % -35.56 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 200
Healthcare Sector # 316
Overall Market # 876


Quick Ratio Statistics
High Average Low
44.49 10.6 0.22
(Dec 31 2021)   (Sep 30 2025)




Financial Statements
Rani Therapeutics Holdings Inc 's Current Liabilities $ 11 Millions Visit RANI's Balance sheet
Rani Therapeutics Holdings Inc 's Cash & cash equivalent $ 53 Millions Visit RANI's Balance sheet
Source of RANI's Sales Visit RANI's Sales by Geography


Cumulative Rani Therapeutics Holdings Inc 's Quick Ratio

RANI's Quick Ratio for the trailling 12 Months

RANI Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -31.06 % -14.43 % 5.9 % 37.44 % 78.94 %
Y / Y Cash & cash equivalent TTM Growth 79.1 % 2.55 % -37.82 % -61.28 % -53.15 %
Quick Ratio TTM 2.7 1.64 1.09 0.73 1.04
Total Ranking TTM # 3556 # 3934 # 1759 # 3132 #
Seq. Current Liabilities TTM Growth -15.19 % -10.53 % -7.93 % -1.32 % 5.26 %
Seq. Cash & cash equivalent TTM Growth 40.17 % 34.47 % 38.15 % -31.22 % -19.74 %

Quick ratio ranking by company, industry and sector >> Back to RANI Financial Strength Comparisons >> Go to Compare RANI Quick Ratio to its Competitors

On the trailing twelve months basis RANI Cash & cash equivalent more than doubled by 422.62 % in Q2 2026 year on year, while Current Liabilities fell to $11 millions, this led to increase in in Rani Therapeutics Holdings Inc 's Quick Ratio to 2.7, Quick Ratio remained below RANI average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 453 other companies have achieved higher Quick Ratio than Rani Therapeutics Holdings Inc . While Quick Ratio overall ranking has improved so far to 3556, from total ranking during the twelve months ending first quarter 2026 at 3934.

Explain Quick Ratio?
How much Cash & cash equivalents RANI´s has?
What are RANI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 454
Healthcare Sector # 920
Within the Market # 3556


trailing twelve months Quick Ratio Statistics
High Average Low
26 4.47 0.28
(Jun 30 2022)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions

Date modified: 2026-09-12T06:25:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.